JP2002537329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002537329A5 JP2002537329A5 JP2000600636A JP2000600636A JP2002537329A5 JP 2002537329 A5 JP2002537329 A5 JP 2002537329A5 JP 2000600636 A JP2000600636 A JP 2000600636A JP 2000600636 A JP2000600636 A JP 2000600636A JP 2002537329 A5 JP2002537329 A5 JP 2002537329A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutical composition
- hydrogen
- alkylamino
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 methylene, difluoromethylene Chemical group 0.000 description 21
- 229910052739 hydrogen Inorganic materials 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 15
- 239000001257 hydrogen Substances 0.000 description 13
- 125000003282 alkyl amino group Chemical group 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 150000002431 hydrogen Chemical group 0.000 description 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical group 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 208000024794 sputum Diseases 0.000 description 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- RXGFWYJPWGAUJS-UHFFFAOYSA-N cyano(nitrosulfonyl)carbamic acid Chemical compound OC(=O)N(C#N)S(=O)(=O)[N+]([O-])=O RXGFWYJPWGAUJS-UHFFFAOYSA-N 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 208000028006 Corneal injury Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 150000003949 imides Chemical group 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 1
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 description 1
- GICKXGZWALFYHZ-UHFFFAOYSA-N 3,N(4)-ethenocytosine Chemical class O=C1NC=CC2=NC=CN12 GICKXGZWALFYHZ-UHFFFAOYSA-N 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical group CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Chemical group CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12175499P | 1999-02-26 | 1999-02-26 | |
| US60/121,754 | 1999-02-26 | ||
| PCT/US2000/005282 WO2000050024A2 (en) | 1999-02-26 | 2000-02-25 | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002537329A JP2002537329A (ja) | 2002-11-05 |
| JP2002537329A5 true JP2002537329A5 (enExample) | 2007-04-19 |
Family
ID=22398588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000600636A Pending JP2002537329A (ja) | 1999-02-26 | 2000-02-25 | 特定のウリジン、アデニン及びシチジン二リン酸並びにそれらの類似体による粘膜水和の促進方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6331529B1 (enExample) |
| EP (1) | EP1161246B1 (enExample) |
| JP (1) | JP2002537329A (enExample) |
| KR (1) | KR20010114214A (enExample) |
| AR (1) | AR023088A1 (enExample) |
| AT (1) | ATE281837T1 (enExample) |
| AU (1) | AU3612600A (enExample) |
| BR (1) | BR0008498A (enExample) |
| CA (1) | CA2359891A1 (enExample) |
| DE (1) | DE60015734D1 (enExample) |
| MX (1) | MXPA01008547A (enExample) |
| WO (1) | WO2000050024A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319908B1 (en) | 1996-07-03 | 2001-11-20 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof |
| US5763447C1 (en) | 1996-07-23 | 2002-05-07 | Inspire Pharmaceuticals | Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds |
| TW593331B (en) | 1997-07-25 | 2004-06-21 | Inspire Pharmaceuticals Inc | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof |
| DK1012154T3 (da) | 1997-07-25 | 2004-07-26 | Inspire Pharmaceuticals Inc | Salte af di(uridin-5'-tetraphosphat), fremgangsmåde til fremstilling og anvendelser deraf |
| US6872710B2 (en) | 1997-07-25 | 2005-03-29 | Inspire Pharmaceuticals, Inc. | Di(uridine 5′)-tetraphosphate and salts thereof |
| US6432454B1 (en) * | 1997-12-12 | 2002-08-13 | C. V. Technologies, Inc. | Processes of making north american ginseng fractions, products containing them, and use as immunomodulators |
| US6624150B2 (en) | 1999-02-26 | 2003-09-23 | Inspire Pharmaceuticals, Inc. | Method of treating gastrointestinal tract disease with purinergic receptor agonists |
| BR0008498A (pt) | 1999-02-26 | 2002-02-05 | Inspire Pharmaceuticals Inc | Método de promoção de hidratação de mucosas com certos difosfatos de uridina, adenina e citidina e seus análogos |
| US6576224B1 (en) | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| US20020061281A1 (en) * | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
| CA2395108A1 (en) * | 1999-12-22 | 2001-06-28 | Inspire Pharmaceuticals, Inc. | Method of treating gastrointestinal tract disease with purinergic receptor agonists |
| US6864243B1 (en) | 2000-05-12 | 2005-03-08 | Inspire Pharmaceuticals, Inc. | Method for treating retinal degeneration with purinergic receptor agonists |
| KR100832821B1 (ko) | 2000-05-30 | 2008-05-28 | 산텐 세이야꾸 가부시키가이샤 | 각막 상피 신장 촉진제 |
| US7452870B2 (en) | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
| US7132408B2 (en) | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US6555675B2 (en) | 2000-08-21 | 2003-04-29 | Inspire Pharmaceuticals, Inc. | Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists |
| US6867199B2 (en) | 2000-08-21 | 2005-03-15 | Inspire Pharmaceuticals, Inc. | Dinucleoside polyphosphate compositions and their therapeutic use |
| WO2003000056A1 (en) | 2001-06-25 | 2003-01-03 | Inspire Pharmaceuticals, Inc. | Joint lubrication with p2y purinergic receptor agonists |
| JP2005532254A (ja) | 2001-11-06 | 2005-10-27 | インスパイアー ファーマシューティカルズ，インコーポレイティド | 炎症性疾患を治療又は予防する方法 |
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US7179481B2 (en) * | 2002-09-19 | 2007-02-20 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
| WO2004037167A2 (en) * | 2002-10-18 | 2004-05-06 | Molichem Medicines, Inc. | Methods of treating dry eye disease with lantibiotics |
| US7056889B2 (en) | 2002-12-16 | 2006-06-06 | Kimberly-Clark, Worldwide, Inc. | Compounds that bind P2Y2 or P2Y1 receptors |
| US6984628B2 (en) * | 2003-07-15 | 2006-01-10 | Allergan, Inc. | Ophthalmic compositions comprising trefoil factor family peptides |
| EP1670474A4 (en) * | 2003-08-18 | 2008-08-06 | Parion Sciences Inc | BLOCKERS OF THE PYRAZINOYL-GUANIDINE SODIUM CHANNEL |
| WO2005115432A2 (en) * | 2004-05-06 | 2005-12-08 | Molichem Medicines, Inc. | Treatment of ocular diseases and disorders using lantibiotic compositions |
| US7326683B2 (en) * | 2004-05-06 | 2008-02-05 | Molichem Medicines, Inc. | Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions |
| US7368439B2 (en) * | 2005-06-15 | 2008-05-06 | Bar - Ilan University | Dinucleoside poly(borano)phosphate derivatives and uses thereof |
| US7851456B2 (en) * | 2005-06-29 | 2010-12-14 | Inspire Pharmaceuticals, Inc. | P2Y6 receptor agonists for treating lung diseases |
| US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| KR100870104B1 (ko) * | 2005-11-28 | 2008-11-26 | 주식회사 머젠스 | 안구건조증 치료 및 예방용 조성물 |
| JP5408882B2 (ja) * | 2008-01-23 | 2014-02-05 | ヤマサ醤油株式会社 | 唾液分泌促進剤 |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| WO2014099673A1 (en) | 2012-12-17 | 2014-06-26 | Parion Sciences, Inc. | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
| US9593084B2 (en) | 2012-12-17 | 2017-03-14 | Parion Sciences, Inc. | Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| KR102883682B1 (ko) | 2016-02-18 | 2025-11-10 | 인버사, 인크. | 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법 |
| US10946034B2 (en) | 2018-03-27 | 2021-03-16 | Invirsa, Inc. | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4753945A (en) | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
| US4868154A (en) | 1986-02-19 | 1989-09-19 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with melanocyte stimulating hormones |
| US5635160A (en) * | 1995-06-07 | 1997-06-03 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions |
| US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| US5900407A (en) * | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
| US5789391A (en) | 1996-07-03 | 1998-08-04 | Inspire Pharmaceuticals, Inc. | Method of treating sinusitis with uridine triphosphates and related compounds |
| US6159952A (en) * | 1996-11-07 | 2000-12-12 | Inspire Pharmaceuticals, Inc. | Method of treating bronchitis with uridine triphosphate and related compounds |
| NZ337225A (en) | 1997-02-06 | 2002-03-28 | Inspire Pharmaceuticals Inc | Dinucleotides useful for treating chronic pulmonary obstructive disorder |
| US6143279A (en) * | 1997-08-29 | 2000-11-07 | The University Of North Carolina At Chapel Hill | Uridine 5'-diphosphate and analogs useful for treating lung diseases |
| BR0008498A (pt) | 1999-02-26 | 2002-02-05 | Inspire Pharmaceuticals Inc | Método de promoção de hidratação de mucosas com certos difosfatos de uridina, adenina e citidina e seus análogos |
-
2000
- 2000-02-25 BR BR0008498-0A patent/BR0008498A/pt not_active Application Discontinuation
- 2000-02-25 AR ARP000100810A patent/AR023088A1/es unknown
- 2000-02-25 MX MXPA01008547A patent/MXPA01008547A/es unknown
- 2000-02-25 CA CA002359891A patent/CA2359891A1/en not_active Abandoned
- 2000-02-25 KR KR1020017010900A patent/KR20010114214A/ko not_active Withdrawn
- 2000-02-25 AU AU36126/00A patent/AU3612600A/en not_active Abandoned
- 2000-02-25 DE DE60015734T patent/DE60015734D1/de not_active Expired - Lifetime
- 2000-02-25 EP EP00914781A patent/EP1161246B1/en not_active Expired - Lifetime
- 2000-02-25 JP JP2000600636A patent/JP2002537329A/ja active Pending
- 2000-02-25 WO PCT/US2000/005282 patent/WO2000050024A2/en not_active Ceased
- 2000-02-25 AT AT00914781T patent/ATE281837T1/de not_active IP Right Cessation
- 2000-02-25 US US09/512,867 patent/US6331529B1/en not_active Expired - Fee Related
-
2001
- 2001-12-03 US US10/005,267 patent/US6436910B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002537329A5 (enExample) | ||
| JP4531867B2 (ja) | 一定のジヌクレオチドおよび粘膜繊毛クリアランスおよび繊毛運動頻度のモジュレーターとしてのそれらの使用 | |
| JP2002516273A5 (enExample) | ||
| JP4399478B2 (ja) | １−（２−（ヒドロキシメチル）−１，３−オキサチオラン−５−イル）−５−フルオロシトシンのｂ型肝炎治療への使用 | |
| EP1087777B1 (en) | Therapeutic dinucleotide and derivatives | |
| TWI271407B (en) | Methods and compositions for treating inflammatory response | |
| US6436910B1 (en) | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof | |
| AU668860B2 (en) | Antiviral nucleoside combination | |
| FI119416B (fi) | L-nukleosidejä hepatiitti-B-viruksen ja Epstein-Barr-viruksen hoitamiseksi | |
| JP2005015491A5 (enExample) | ||
| JP2008505902A5 (enExample) | ||
| GB2181128A (en) | 3'-azidonucleosides | |
| EA021377B1 (ru) | Модуляторы толлподобных рецепторов | |
| WO2000030629A2 (en) | Method of promoting cervical and vaginal secretions | |
| JP2002505337A5 (enExample) | ||
| US6555675B2 (en) | Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists | |
| CN1413113A (zh) | 使用嘌呤能受体激动剂治疗胃肠道疾病的方法 | |
| JP2005532254A (ja) | 炎症性疾患を治療又は予防する方法 | |
| Johnson et al. | Prostaglandin E2 of the upper aerodigestive tract | |
| JP2004511542A (ja) | 煙の吸入の治療のためのｐ３８阻害剤の使用 | |
| EP0979650A1 (en) | Antiviral agents | |
| WO2025100427A1 (ja) | 肺高血圧症の予防および／または治療用医薬 | |
| US20090004101A1 (en) | Method and Means for Enhanced Pulmonary Drug Delivery | |
| ZA200200129B (en) | Conjugates of sodium channel blockers and methods of using the same. |